替考拉宁对当代全球范围内金黄色葡萄球菌分离株的体外活性研究。
In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
机构信息
JMI Laboratories, North Liberty, IA 52317, USA.
出版信息
Antimicrob Agents Chemother. 2010 Jun;54(6):2704-6. doi: 10.1128/AAC.00301-10. Epub 2010 Apr 12.
Abstract
The activity of telavancin and comparators was assessed against a contemporary (2007 and 2008) global collection of 10,000 isolates of Staphylococcus aureus. Telavancin was very active against methicillin-susceptible and -resistant S. aureus (MSSA and MRSA, respectively; MIC(50/90) for both, 0.12/0.25 microg/ml; 100.0% susceptible). This agent was 2-, 4-, and 8-fold more potent than daptomycin (MIC(90), 0.5 microg/ml), vancomycin or quinupristin-dalfopristin (MIC(90), 1 microg/ml), and linezolid (MIC(90), 2 microg/ml) against MRSA, respectively. These data show a potent activity of telavancin tested against a current global collection of S. aureus.
摘要
替考拉宁对万古霉素敏感和耐药金黄色葡萄球菌（分别为 MSSA 和 MRSA；MIC（50/90）均为 0.12/0.25μg/ml；100.0%敏感）的活性进行了评估。与达托霉素（MIC（90）为 0.5μg/ml）、万古霉素或奎奴普丁/达福普汀（MIC（90）为 1μg/ml）和利奈唑胺（MIC（90）为 2μg/ml）相比，该药物对 MRSA 的活性分别高出 2、4 和 8 倍。这些数据显示了替考拉宁对当前全球金黄色葡萄球菌分离株的强大活性。
相似文献
1
In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
Antimicrob Agents Chemother. 2010 Jun;54(6):2704-6. doi: 10.1128/AAC.00301-10. Epub 2010 Apr 12.
2
Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies.
Antimicrob Agents Chemother. 2009 Oct;53(10):4217-24. doi: 10.1128/AAC.00742-09. Epub 2009 Jul 20.
3
Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.
Eur J Clin Microbiol Infect Dis. 2019 Dec;38(12):2323-2330. doi: 10.1007/s10096-019-03683-z. Epub 2019 Aug 24.
4
In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Microb Drug Resist. 2003 Winter;9(4):389-93. doi: 10.1089/107662903322762833.
5
Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
Antimicrob Agents Chemother. 2013 Jul;57(7):3178-81. doi: 10.1128/AAC.00484-13. Epub 2013 Apr 29.
6
Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S.aureus from the Oslo area.
Scand J Infect Dis. 2007;39(11-12):1059-62. doi: 10.1080/00365540701466231. Epub 2007 Jul 30.
7
Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
Antimicrob Agents Chemother. 2010 May;54(5):2212-5. doi: 10.1128/AAC.01653-09. Epub 2010 Feb 22.
8
Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02397-17. Print 2018 Mar.
9
Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2008 Aug;52(8):2974-6. doi: 10.1128/AAC.00257-08. Epub 2008 Jun 2.
10
In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
Antimicrob Agents Chemother. 2010 Sep;54(9):3799-803. doi: 10.1128/AAC.00452-10. Epub 2010 Jun 28.
引用本文的文献
1
Physiologically Based Pharmacokinetic Modeling for Trimethoprim and Sulfamethoxazole in Children.
Clin Pharmacokinet. 2019 Jul;58(7):887-898. doi: 10.1007/s40262-018-00733-1.
2
Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01813-17. Print 2018 Jan.
3
Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
Clin Infect Dis. 2015 Mar 1;60(5):787-96. doi: 10.1093/cid/ciu971. Epub 2014 Dec 3.
4
Studies on in vitro interaction of ampicillin and fresh garlic extract against Staphylococcus aureus by checkerboard method.
Anc Sci Life. 2013 Oct;33(2):114-8. doi: 10.4103/0257-7941.139053.
5
Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents.
Antimicrob Agents Chemother. 2012 Jul;56(7):3999-4004. doi: 10.1128/AAC.00011-12. Epub 2012 Apr 16.
6
Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections.
Infect Drug Resist. 2011;4:87-95. doi: 10.2147/IDR.S5327. Epub 2011 Mar 10.
7
Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin.
Antimicrob Agents Chemother. 2010 Dec;54(12):5376-8. doi: 10.1128/AAC.00857-10. Epub 2010 Sep 27.
本文引用的文献
1
Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
Antimicrob Agents Chemother. 2009 Aug;53(8):3375-83. doi: 10.1128/AAC.01710-08. Epub 2009 May 26.
2
Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens.
Clin Microbiol Infect. 2009 Mar;15(3):218-23. doi: 10.1111/j.1469-0691.2009.02740.x.
3
NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007.
Infect Control Hosp Epidemiol. 2008 Nov;29(11):996-1011. doi: 10.1086/591861.
4
A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI).
Ther Clin Risk Manag. 2008 Feb;4(1):235-44. doi: 10.2147/tcrm.s1843.
5
Management of methicillin-resistant Staphylococcus aureus bacteremia.
Clin Infect Dis. 2008 Jun 1;46 Suppl 5:S386-93. doi: 10.1086/533595.
6
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Clin Infect Dis. 2008 Jun 1;46(11):1683-93. doi: 10.1086/587896.
7
In vitro activity of telavancin against resistant gram-positive bacteria.
Antimicrob Agents Chemother. 2008 Jul;52(7):2647-52. doi: 10.1128/AAC.01398-07. Epub 2008 Apr 28.
8
Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
Antimicrob Agents Chemother. 2008 Jul;52(7):2383-8. doi: 10.1128/AAC.01641-07. Epub 2008 Apr 28.
9
In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative.
J Antimicrob Chemother. 2008 Jul;62(1):116-21. doi: 10.1093/jac/dkn124. Epub 2008 Apr 19.
10
Key considerations in the treatment of complicated staphylococcal infections.
Clin Microbiol Infect. 2008 Mar;14 Suppl 2:3-9. doi: 10.1111/j.1469-0691.2008.01923.x.
Zotero 插件